Molecular and therapeutic potential and toxicity of valproic acid

S Chateauvieux, F Morceau, M Dicato… - BioMed Research …, 2010 - Wiley Online Library
Valproic acid (VPA), a branched short‐chain fatty acid, is widely used as an antiepileptic
drug and a mood stabilizer. Antiepileptic properties have been attributed to inhibition of …

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

O Khan, NB La Thangue - Immunology and cell biology, 2012 - Wiley Online Library
Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad
repertoire of physiological processes, many of which are aberrantly controlled in tumor cells …

Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects

H Julkunen, A Cichonska, P Gautam… - Nature …, 2020 - nature.com
We present comboFM, a machine learning framework for predicting the responses of drug
combinations in pre-clinical studies, such as those based on cell lines or patient-derived …

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

K Keller, M Jung - Epigenetic Therapy of Cancer: Preclinical Models and …, 2013 - Springer
Histone deacetylases are key enzymes of epigenetic regulation and are therefore involved
in crucial cellular events like transcription, differentiation, apoptosis and cell division. The …

Tumours associated with BAP1 mutations

R Murali, T Wiesner, RA Scolyer - Pathology, 2013 - Elsevier
Summary BAP1 (BRCA1-Associated Protein 1) was initially identified as a protein that binds
to BRCA1. BAP1 is a tumour suppressor that is believed to mediate its effects through …

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma

S Landreville, OA Agapova, KA Matatall, ZT Kneass… - Clinical cancer …, 2012 - AACR
Purpose: Metastasis is responsible for the death of most cancer patients, yet few therapeutic
agents are available which specifically target the molecular events that lead to metastasis …

Epigenetic treatment of solid tumours: a review of clinical trials

C Nervi, E De Marinis, G Codacci-Pisanelli - Clinical epigenetics, 2015 - Springer
Epigenetic treatment has been approved by regulatory agencies for haematological
malignancies. The success observed in cutaneous lymphomas represents a proof of …

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection

T Roger, J Lugrin, D Le Roy, G Goy… - Blood, The Journal …, 2011 - ashpublications.org
Regulated by histone acetyltransferases and deacetylases (HDACs), histone acetylation is a
key epigenetic mechanism controlling chromatin structure, DNA accessibility, and gene …

[HTML][HTML] Hidden pharmacological activities of valproic acid: A new insight

D Singh, S Gupta, I Verma, MA Morsy, AB Nair… - Biomedicine & …, 2021 - Elsevier
Valproic acid (VPA) is an approved drug for managing epileptic seizures, bipolar disorders,
and migraine. VPA has been shown to elevate the level of gamma-aminobutyric acid …

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

M Weller, T Gorlia, JG Cairncross, MJ Van Den Bent… - Neurology, 2011 - AAN Enterprises
Objective: This analysis was performed to assess whether antiepileptic drugs (AEDs)
modulate the effectiveness of temozolomide radiochemotherapy in patients with newly …